The biochemical basis of the very low baseline FAP levels and absent or negligible upregulation of FAP after treatment with recombinant TGFbeta-1 in glioma stem-like cells and human umbilical vein endothelial cells (HUVEC) is, at present, unknown. The gene discussed is FAP; the disease is glioma.